台灣台中2021年4月12日 /美通社/ — 台灣骨王生技今（12）日宣布，「OOOPDS 3D重建與手術計畫醫療軟體」日前通過衛福部TFDA認證及產品上市資格，成為國內3D功能最齊全的醫療用手術計畫軟體，骨王公司下一步也將申請美國FDA認證，進軍3D列印醫材的全球市場。
SURGLASSES announced today that its "OOOPDS 3D Reconstruction and Surgical Planning Medical Software" recently passed certification from Taiwan's Ministry of Health and Welfare TFDA (Taiwan Food and Drug Administration) and is now qualified for product launch.
In recent years, international 3D printing technology has gradually matured and been applied in various medical fields, including orthopedics, spine, and dentistry. However, due to limited regulatory support, the availability of 3D surgical planning medical software that supports 3D printing remains relatively scarce. The primary reasons include the difficulty and time-consuming nature of developing medical software, as well as insufficient regulatory knowledge. As many of us understand, utilizing 3D printing to convert files from computed tomography (CT) and magnetic resonance imaging (MRI) scans into surgical plans, and even designing reference models and implants, creates customized implants directly tailored to patients' needs. This approach is considered the optimal solution as it is both economical and efficient. It significantly reduces surgical time, enhances patient satisfaction, and accelerates patient recovery. For more information, please visit the SURGLASSES official website at www.surglasses.com.
CEO Wang Minliang stated that SURGLASSES is renowned for developing the world's first smart surgical glasses. Currently, these smart surgical glasses have obtained CE certification from the European Union, and the product has been deployed in regions including the United Kingdom, Europe, the Middle East, India, and Russia. However, Wang emphasized that SURGLASSES‘s innovative research and development stem from its complete mastery of medical software. After extensive patent layouts, various products are currently undergoing certification processes in different countries.
Related News
#CISION #CISION-EN
